London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: Troajan, 2 May 2023 22:26
Last post: Troajan, 2 May 2023 22:26
Started: CAGNEY, 9 Apr 2023 18:16
Last post: FIREGUYUK, 21 Apr 2023 23:02
Have a look at TILS - the directors totally messed that up
I hold 690k of Okyo in Crest.
I
I bought at an average of 4.8p so down quite a bit.I do think that this company will do very well in the future.Been dabbling on the stock market for a number of years, but this is the first time I'v experienced moving the whole company dealing to the USA.Does anyone know if it's difficult to deal with the Dow ?Information will be welcomed.
Started: CityWatcher, 6 Apr 2023 07:20
Last post: CityWatcher, 6 Apr 2023 07:20
With their intention of delisting from the aim & also consolidating the shares, this company is a sell for anyone holding in certificate form. Complex to get reissued in a proper holding online, it's advised to sell up now & just accept any loss. Reinvesting any monies in Genedrive will for sure benefit your wealth.
Started: ChiefScout, 17 Feb 2023 17:14
Last post: johndean, 4 Apr 2023 12:13
what happens to the shares we hold?
another stitch up PI company by Gabriele Cerrone
G.C. Filling his boots :-)
What the .ell happened there ? It's been Sleepy valley for months.
Started: mpap3056, 18 Mar 2023 15:10
Last post: rp6577, 23 Mar 2023 10:06
1 Nasdaq share for every 65 ordinary shares. Although there always appears to be a slightly higher comparative price in the US
Hi
Can anyone please explain why price difference at london stock exchange 2.75 and nasdaq 1.55/
Thanks
Started: Yorkshireboy, 26 Feb 2023 17:54
Last post: moneybags1, 26 Feb 2023 20:41
Dry Eye Disease is certainly very common, and certainly as a GP I used to see a couple of cases a week.
The science here looks pretty solid, and with clinical trials due to start any day now things are starting to get exciting.
....Still slightly concerned at the horrendous spread this trades on (even though you can generally trade well inside this)
A sniff of positive results here and OKYO will really take off!
Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren’t Fully Effective – OKYO Pharma’s Drug Candidate Could Be The Solution - OKYO Pharma (NASDAQ:OKYO) - Benzinga
Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution | Benzinga
Good Luck Everyone
Not that I could see. I decided to sell my position. Will sit and see what it does next week. Always wary of big moves without news. They so often retrace
Any news here? Huge volume on Nasdaq
Started: Hufc1908, 28 Dec 2022 16:32
Last post: Hufc1908, 28 Dec 2022 16:32
@ZaksTradersCafe 20 Small Caps For 2023. The Countdown Begins.
20) OKYO Pharma (#OKYO): 2.75p Target 7p
19) Polarean (#POLX): 49p Target 150p
18) Baron Oil (#BOIL): 0.14p Target 0.3p
17) Hvivo (#HVO): 10p Target 20p
16) GreenX Metals (#GRX): 33p Target 50p
https://twitter.com/Share_Talk/status/1608072972094345217?s=20
Such an accelerated approved clearly means that the costs of development are that much more economic. Finally, given the way that the market cap is back to where it was two years ago, despite the advances made, we should see a realignment in 2023, especially given the drug will be “moving into the clinic in the first quarter of 2023.
https://www.share-talk.com/zak-mir-20-small-caps-for-2023-countdown-20-to-16/
Started: BD6Vant, 12 Sep 2022 11:04
Last post: BD6Vant, 12 Sep 2022 11:04
Posted over on ADVFN and very interesting watch:
https://youtu.be/qC6PYmkS4sY
Started: Whitney1, 2 Sep 2022 19:41
Last post: Whitney1, 2 Sep 2022 19:41
This is the comment that is creating the significant interest, particularly over in the US:
Biotechnology company intends to file a investigational new drug filing to the US Food & Drug Administration of OK-101 for the treatment of Dry Eye Disease......
Possible tap in to Multi-Billion Dollar Market opportunity in the making.
Started: Whitney1, 30 Aug 2022 09:56
Last post: Whitney1, 30 Aug 2022 09:56
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm
· OK-101 to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain.
· Successful pre-IND meeting with FDA in Q1 2022 and novel speed to market potential.
· IND filing on OK-101 to treat DED planned for Q4 2022, with first human trial designed as Phase 2 trial planned to begin in Q1 2023.
· Multibillion-dollar DED market whose medical needs remain largely unmet.
· AmbioPharm supporting OK-101 program with peptide synthesis and development.
Started: Rob1967, 24 May 2022 11:58
Last post: rp6577, 25 May 2022 09:16
A lot of small bios are valued at cash level or below. I don’t think Okyo has much cash so it is still relatively quite highly valued, which is why I think it is under pressure
Why is this stock dropping off the back of no news and the only recent news was good news ?? I dont get it
Started: CAGNEY, 18 May 2022 16:59
Last post: CAGNEY, 18 May 2022 16:59
Surely to be accepted on the USA stock listing has got to be a good sign and a confidence booster????.
Started: BoNidel, 15 Dec 2021 08:05
Last post: Alwaysone, 18 May 2022 16:50
Like I said further back here
What a dog of a share this is, just like the one the bods are attached to ( TILS) Tiziana Life Sciences
What a dog of a share this is, just like the one the bods are attached to ( TILS) Tiziana Life Sciences
I have to second Bones warning. I am normally an optimist, but that has been dented by the Tweedle Dum and Tweedle Dee of Tiziana and Accustem, Gabriele Certone and Kunwar Shailubhai. OKYO belongs to the same stable of biotech startups of Gabriele's. I hope this product works out for OKYO but between now and trials in q3, the sp is only going one way without further news. And seeing how they have acted over at TiziAana that may be exactly what they want.
I strongly advise anyone that’s considering investing here to check out Tiziana life sciences. The key players here such as Gabrielle Cerrone & Kunwar Shailubhai (recently stepped down) have missed enormous deadlines with no comment for the past 12 months, have demerger Another business (Accustem sciences) which still hasn’t listed for around 12 months & now have moved from the main market LSE listing to NASDAQ only and many uk shareholders still aren’t able to trade after around 55 days with the share price dropping daily & down around 80% since last year with no comment from the BOD or updates!
I would advise extreme caution here as the tactics were similar last year when the same people pumped Tiziana/TILS/TLSA with a pile of RNS then did a £57m raise & have since just disappeared really.
Spread the word
Started: dp192, 17 May 2022 16:49
Last post: dp192, 17 May 2022 16:49
lots of attention on the ADS shares listed over the pond today, seen two upward halts already
Last post: Troajan, 23 Feb 2022 10:21
Last post: Cloudy390, 22 Feb 2022 14:22
Fund raise next!
Started: nomlungu, 21 Feb 2022 17:04
Last post: nomlungu, 21 Feb 2022 17:04
I would think the SP is sinking because if they do do a P2 trial a big fund raise will occur , diluting all share holders and take them into billions of shares. IMO
Why o Why is it falling. Cant see any negative in the RNS.
Infact, they are now fully focusing on 101.
The cash has gone down but isnt that already expected.
May buy more later.
Started: appletree1, 4 Jan 2022 14:25
Last post: guygad, 27 Jan 2022 04:55
Am reasonably sure Zak tipped in in his 2021 list.
"13. Okyo Pharma (OKYO): 7p Target 20p
We stick with an unloved biotech for the next stock in the Top 20, much of which is based not only on the fundamental value behind a company, but also the acknowledgement that H2 2021 has been brutal as far as the small cap space has been concerned. We have been treated to delayed / overpriced IPOs, and stock margins being raised at the drop of a hat, something which quite understandably might have caused some to chance their arm in the wild west of crypto trading. For Okyo Pharma, 2022 looks to be a comeback year. It has been gestating its dry eye treatment, something which was well flagged in July with the tie up with Ora. It would appear that professional investors started appreciating what is to come from the early autumn, with the shares gapping up from 4p. Indeed, OK-101 is a wonderfully subtle and game changing treatment, able to bind to the surface of the eye, to target the inflammatory cells. One would assume that the reason that shares of Okyo are not much higher than they are is that investors have perhaps not taken the time to appreciate the advance that OKYO has made. Indeed, they have also not appreciated the recent announcements that not only has U.S. Patent issued for use of OK-101 to treat dry eye disease, but that OK-101 is to skip straight to Phase 2 human clinical trials in H2 next year. Given the size of the market, the breakthrough, and the strength of the IP, it can be said that genuine blockbuster drugs do not come much quicker, cheaper, or with greater application than the one that OKYO has under its wing."
Started: Troajan, 6 Dec 2021 08:37
Last post: Troajan, 13 Dec 2021 10:38
Started: ZaphodBeeblebrox, 6 Dec 2021 07:56
Last post: ZaphodBeeblebrox, 6 Dec 2021 07:56
IND Q3 2022
Phase 2 trial Q4 2022 run by Ora.
Better late than never.
No comment from the AWOL chairman Gabriele Cerrone.
Started: rp6577, 24 Nov 2021 14:27
Last post: rp6577, 24 Nov 2021 14:27
It get the feeling that something is going to happen soon. Price is trickling up and it has been so long since we had some proper news
Hello Cagney, I have had my tear ducts blocked and I use artificial tears but when they were really sore after having my first child - think it was hormone related (I’m a lady -Fred’s my lucky name)! my eyes kept getting infected and it’s like having sawdust in your eyes! But loads of conditions have dry eyes as a side effect.
Nice to see SP up today though!
Hello Fred.What is the cause of your condition,it must be really sore and painful,what do you use to ease the problem?The body is so complicated,there's so many things that can go awry with it,so lets hope Okyo can become your knight in shinning armour.